RESUMEN
Mucopolysaccharidoses (MPSs) are rare inherited lysosomal storage diseases (LSDs) caused by deficient activity in one of the enzymes responsible for glycosaminoglycans lysosomal degradation. MPS II is caused by pathogenic mutations in the IDS gene, leading to deficient activity of the enzyme iduronate-2-sulfatase, which causes dermatan and heparan sulfate storage in the lysosomes. In MPS VI, there is dermatan sulfate lysosomal accumulation due to pathogenic mutations in the ARSB gene, leading to arylsulfatase B deficiency. Alterations in the immune system of MPS mouse models have already been described, but data concerning MPSs patients is still scarce. Herein, we study different leukocyte populations in MPS II and VI disease patients. MPS VI, but not MPS II patients, have a decrease percentage of natural killer (NK) cells and monocytes when compared with controls. No alterations were identified in the percentage of T, invariant NKT, and B cells in both groups of MPS disease patients. However, we discovered alterations in the naïve versus memory status of both helper and cytotoxic T cells in MPS VI disease patients compared to control group. Indeed, MPS VI disease patients have a higher frequency of naïve T cells and, consequently, lower memory T cell frequency than control subjects. Altogether, these results reveal MPS VI disease-specific alterations in some leukocyte populations, suggesting that the type of substrate accumulated and/or enzyme deficiency in the lysosome may have a particular effect on the normal cellular composition of the immune system.
RESUMEN
BACKGROUND: Endogenously released adenine and uracil nucleotides favour the osteogenic commitment of bone marrow-derived mesenchymal stromal cells (BM-MSCs) through the activation of ATP-sensitive P2X7 and UDP-sensitive P2Y6 receptors. Yet, these nucleotides have their osteogenic potential compromised in post-menopausal (Pm) women due to overexpression of nucleotide metabolizing enzymes, namely NTPDase3. This prompted us to investigate whether NTPDase3 gene silencing or inhibition of its enzymatic activity could rehabilitate the osteogenic potential of Pm BM-MSCs. METHODS: MSCs were harvested from the bone marrow of Pm women (69 ± 2 years old) and younger female controls (22 ± 4 years old). The cells were allowed to grow for 35 days in an osteogenic-inducing medium in either the absence or the presence of NTPDase3 inhibitors (PSB 06126 and hN3-B3s antibody); pre-treatment with a lentiviral short hairpin RNA (Lenti-shRNA) was used to silence the NTPDase3 gene expression. Immunofluorescence confocal microscopy was used to monitor protein cell densities. The osteogenic commitment of BM-MSCs was assessed by increases in the alkaline phosphatase (ALP) activity. The amount of the osteogenic transcription factor Osterix and the alizarin red-stained bone nodule formation. ATP was measured with the luciferin-luciferase bioluminescence assay. The kinetics of the extracellular ATP (100 µM) and UDP (100 µM) catabolism was assessed by HPLC RESULTS: The extracellular catabolism of ATP and UDP was faster in BM-MSCs from Pm women compared to younger females. The immunoreactivity against NTPDase3 increased 5.6-fold in BM-MSCs from Pm women vs. younger females. Selective inhibition or transient NTPDase3 gene silencing increased the extracellular accumulation of adenine and uracil nucleotides in cultured Pm BM-MSCs. Downregulation of NTPDase3 expression or activity rehabilitated the osteogenic commitment of Pm BM-MSCs measured as increases in ALP activity, Osterix protein cellular content and bone nodule formation; blockage of P2X7 and P2Y6 purinoceptors prevented this effect. CONCLUSIONS: Data suggest that NTPDase3 overexpression in BM-MSCs may be a clinical surrogate of the osteogenic differentiation impairment in Pm women. Thus, besides P2X7 and P2Y6 receptors activation, targeting NTPDase3 may represent a novel therapeutic strategy to increase bone mass and reduce the osteoporotic risk of fractures in Pm women.
Asunto(s)
Células Madre Mesenquimatosas , Osteogénesis , Humanos , Femenino , Anciano , Adolescente , Adulto Joven , Adulto , Posmenopausia , Células Madre Mesenquimatosas/metabolismo , Diferenciación Celular , Nucleótidos de Uracilo/metabolismo , Nucleótidos de Uracilo/farmacología , Uridina Difosfato/metabolismo , Uridina Difosfato/farmacología , Adenosina Trifosfato/metabolismo , Células de la Médula Ósea , Células CultivadasRESUMEN
BACKGROUND: Niemann-Pick type C (NPC, MIM #257220) is a neuro-visceral disease, caused predominantly by pathogenic variants in the NPC1 gene. Here we studied patients with clinical diagnosis of NPC but inconclusive results regarding the molecular analysis. METHODS: We used a Next-Generation Sequencing (NGS)-panel followed by cDNA analysis. Latter, we used massively parallel single-cell RNA-seq (MARS-Seq) to address gene profiling changes and finally the effect of different variants on the protein and cellular levels. RESULTS: We identified novel variants and cDNA analysis allowed us to establish the functional effect of a silent variant, previously reported as a polymorphism. We demonstrated that this variant induces the skipping of exon 11 leading to a premature stop codon and identified it in NPC patients from two unrelated families. MARS-Seq analysis showed that a number of upregulated genes were related to the unfolded protein response (UPR) and endoplasmic reticulum (ER) stress in one specific patient. Also, for all analyzed variants, the NPC1 protein was partially retained in the ER. CONCLUSION: We showed that the NPC1 silent polymorphism (p.V562V) is a disease-causing variant in NPC and that the UPR is upregulated in an NPC patient.
Asunto(s)
Péptidos y Proteínas de Señalización Intracelular/genética , Enfermedad de Niemann-Pick Tipo C/genética , Mutación Silenciosa , Respuesta de Proteína Desplegada , Células Cultivadas , Niño , Exones , Fibroblastos/metabolismo , Humanos , Péptidos y Proteínas de Señalización Intracelular/metabolismo , Proteína Niemann-Pick C1 , Enfermedad de Niemann-Pick Tipo C/metabolismo , Empalme del ARNRESUMEN
Lysosomal storage diseases (LSDs) are a heterogeneous group of genetic disorders with variable degrees of severity and a broad phenotypic spectrum, which may overlap with a number of other conditions. While individually rare, as a group LSDs affect a significant number of patients, placing an important burden on affected individuals and their families but also on national health care systems worldwide. Here, we present our results on the use of an in-house customized next-generation sequencing (NGS) panel of genes related to lysosome function as a first-line molecular test for the diagnosis of LSDs. Ultimately, our goal is to provide a fast and effective tool to screen for virtually all LSDs in a single run, thus contributing to decrease the diagnostic odyssey, accelerating the time to diagnosis. Our study enrolled a group of 23 patients with variable degrees of clinical and/or biochemical suspicion of LSD. Briefly, NGS analysis data workflow, followed by segregation analysis allowed the characterization of approximately 41% of the analyzed patients and the identification of 10 different pathogenic variants, underlying nine LSDs. Importantly, four of those variants were novel, and, when applicable, their effect over protein structure was evaluated through in silico analysis. One of the novel pathogenic variants was identified in the GM2A gene, which is associated with an ultra-rare (or misdiagnosed) LSD, the AB variant of GM2 Gangliosidosis. Overall, this case series highlights not only the major advantages of NGS-based diagnostic approaches but also, to some extent, its limitations ultimately promoting a reflection on the role of targeted panels as a primary tool for the prompt characterization of LSD patients.
Asunto(s)
Marcadores Genéticos , Predisposición Genética a la Enfermedad , Pruebas Genéticas , Variación Genética , Secuenciación de Nucleótidos de Alto Rendimiento/métodos , Enfermedades por Almacenamiento Lisosomal/diagnóstico , Lisosomas/patología , Salud Global , Humanos , Enfermedades por Almacenamiento Lisosomal/genética , Lisosomas/genética , Análisis de Secuencia de ADNRESUMEN
BACKGROUND, AIMS AND METHODS: The α-galactosidase gene (GLA) c.337T>C/p.Phe113Leu variant was originally described in patients with late-onset cardiac forms of Fabry disease (FD), who had residual α-galactosidase activity. It has since emerged as the most commonly reported GLA variant in Portuguese subjects diagnosed with FD but is also prevalent in the Italian population, where two boys carrying the GLA Leu113 allele were identified in a large-scale newborn screening program, the variant allele segregating in both cases with the same surrounding haplotype. To further delineate the genotype-phenotype correlations of this GLA variant, we have reviewed the natural history and clinical phenotypes of 11 symptomatic Portuguese males, from 10 unrelated families originating from several different areas in mainland Portugal and Madeira Island, who were diagnosed with FD associated with the GLA Leu113 allele in a diversity of clinical and screening settings. Nine of the patients were the probands of their respective families. To test whether the GLA Leu113 allele inherited by the 10 Portuguese and the two Italian families resulted from independent mutational events, we have additionally performed a haplotype analysis with 5 highly polymorphic, closely linked microsatellite markers surrounding the GLA gene. RESULTS AND CONCLUSIONS: Hemizygosity for the GLA Leu113 variant allele is associated with a late-onset form of FD, invariably presenting with severe cardiac involvement. Clinically relevant cerebrovascular and kidney involvement may also occur in some patients but the pathogenic relationship between the incomplete α-galactosidase deficiency and the risks of stroke and of chronic kidney disease is not straightforward. The observation that the Leu113 allele segregated within the same GLA microsatellite haplotype in both the Portuguese and Italian families suggests its inheritance from a common ancestor.
Asunto(s)
Enfermedad de Fabry/diagnóstico , Enfermedad de Fabry/genética , alfa-Galactosidasa/genética , alfa-Galactosidasa/metabolismo , Adulto , Anciano , Alelos , Enfermedades Cardiovasculares/complicaciones , Enfermedades Cardiovasculares/genética , Enfermedades Cardiovasculares/metabolismo , Trastornos Cerebrovasculares/complicaciones , Trastornos Cerebrovasculares/genética , Trastornos Cerebrovasculares/metabolismo , Enfermedad de Fabry/complicaciones , Enfermedad de Fabry/diagnóstico por imagen , Estudios de Asociación Genética , Genotipo , Haplotipos , Humanos , Italia/epidemiología , Masculino , Repeticiones de Microsatélite/genética , Persona de Mediana Edad , Mutación , Miocitos Cardíacos/patología , Miocitos Cardíacos/ultraestructura , Fenotipo , Portugal/epidemiología , Insuficiencia Renal Crónica/complicaciones , Insuficiencia Renal Crónica/genética , Insuficiencia Renal Crónica/metabolismo , Factores de RiesgoRESUMEN
The direct detrusor relaxant effect of ß3-adrenoceptor agonists as a primary mechanism to improve overactive bladder symptoms has been questioned. Among other targets, activation of ß3-adrenoceptors downmodulate nerve-evoked acetylcholine (ACh) release, but there is insufficient evidence for the presence of these receptors on bladder cholinergic nerve terminals. Our hypothesis is that adenosine formed from the catabolism of cyclic AMP in the detrusor may act as a retrograde messenger via prejunctional A1 receptors to explain inhibition of cholinergic activity by ß3-adrenoceptors. Isoprenaline (1 µM) decreased [3H]ACh release from stimulated (10 Hz, 200 pulses) human (-47 ± 5%) and rat (-38 ± 1%) detrusor strips. Mirabegron (0.1 µM, -53 ± 8%) and CL316,243 (1 µM, -37 ± 7%) mimicked isoprenaline (1 µM) inhibition, and their effects were prevented by blocking ß3-adrenoceptors with L748,337 (30 nM) and SR59230A (100 nM), respectively, in human and rat detrusor. Mirabegron and isoprenaline increased extracellular adenosine in the detrusor. Blockage of A1 receptors with 1,3-dipropyl-8-cyclopentylxanthine (DPCPX, 100 nM) or the equilibrative nucleoside transporters (ENT) with dipyridamole (0.5 µM) prevented mirabegron and isoprenaline inhibitory effects. Dipyridamole prevented isoprenaline-induced adenosine outflow from the rat detrusor, and this effect was mimicked by the ENT1 inhibitor, S-(4-nitrobenzyl)-6-thioinosine (NBTI, 30 µM). Cystometry recordings in anesthetized rats demonstrated that SR59230A, DPCPX, dipyridamole, and NBTI reversed the decrease in the voiding frequency caused by isoprenaline (0.1-1,000 nM). Data suggest that inhibition of cholinergic neurotransmission by ß3-adrenoceptors results from adenosine release via equilibrative nucleoside transporters and prejunctional A1-receptor stimulation in human and rat urinary bladder.
Asunto(s)
Acetilcolina/metabolismo , Adenosina/metabolismo , Fibras Colinérgicas/metabolismo , Inhibición Neural , Terminales Presinápticos/metabolismo , Receptor de Adenosina A1/metabolismo , Receptores Adrenérgicos beta 3/metabolismo , Transmisión Sináptica , Vejiga Urinaria/inervación , Antagonistas del Receptor de Adenosina A1/farmacología , Agonistas de Receptores Adrenérgicos beta 3/farmacología , Antagonistas de Receptores Adrenérgicos beta 3/farmacología , Adulto , Animales , Fibras Colinérgicas/efectos de los fármacos , AMP Cíclico/metabolismo , Proteínas de Transporte de Nucleósido Equilibrativas/metabolismo , Humanos , Técnicas In Vitro , Masculino , Persona de Mediana Edad , Inhibición Neural/efectos de los fármacos , Inhibidores de Fosfodiesterasa/farmacología , Terminales Presinápticos/efectos de los fármacos , Ratas Wistar , Receptor de Adenosina A1/efectos de los fármacos , Receptores Adrenérgicos beta 3/efectos de los fármacos , Transmisión Sináptica/efectos de los fármacos , Factores de Tiempo , Micción , UrodinámicaRESUMEN
PURPOSE: Deregulation of purinergic bladder signaling may contribute to persistent detrusor overactivity in patients with bladder outlet obstruction. Activation of uridine diphosphate sensitive P2Y6 receptors increases voiding frequency in rats indirectly by releasing adenosine triphosphate from the urothelium. To our knowledge this mechanism has never been tested in the human bladder. MATERIALS AND METHODS: We examined the role of the uridine diphosphate sensitive P2Y6 receptor on tetrodotoxin insensitive nonneuronal adenosine triphosphate and [(3)H]acetylcholine release from the human urothelium with the lamina propria of control organ donors and patients with benign prostatic hyperplasia. RESULTS: The adenosine triphosphate-to-[(3)H]acetylcholine ratio was fivefold higher in mucosal urothelium/lamina propria strips from benign prostatic hyperplasia patients than control men. The selective P2Y6 receptor agonist PSB0474 (100 nM) augmented by a similar amount adenosine triphosphate and [(3)H]acetylcholine release from mucosal urothelium/lamina propria strips from both groups of individuals. The facilitatory effect of PSB0474 was prevented by MRS2578 (50 nM) and by carbenoxolone (10 µM), which block P2Y6 receptor and pannexin-1 hemichannels, respectively. Blockade of P2X3 (and/or P2X2/3) receptors with A317491 (100 nM) also attenuated release facilitation by PSB0474 in control men but not in patients with benign prostatic hyperplasia. Immunolocalization studies showed that P2Y6, P2X2 and P2X3 receptors were present in choline acetyltransferase positive urothelial cells. In contrast to P2Y6 staining, choline acetyltransferase, P2X2 and P2X3 immunoreactivity decreased in the urothelium of benign prostatic hyperplasia patients. CONCLUSIONS: Activation of P2Y6 receptor amplifies mucosal adenosine triphosphate release underlying bladder overactivity in patients with benign prostatic hyperplasia. Therefore, we propose selective P2Y6 receptor blockade as a novel therapeutic strategy to control persistent storage symptoms in obstructed patients.
Asunto(s)
Acetilcolina/metabolismo , Adenosina Trifosfato/metabolismo , Receptores Purinérgicos P2/fisiología , Obstrucción del Cuello de la Vejiga Urinaria/metabolismo , Vejiga Urinaria/metabolismo , Urotelio/metabolismo , Anciano , Humanos , Masculino , Membrana Mucosa/metabolismo , Hiperplasia Prostática/complicaciones , Obstrucción del Cuello de la Vejiga Urinaria/etiologíaRESUMEN
AMP dephosphorylation via ecto-5'-nucleotidase/CD73 is the rate limiting step to generate extracellular adenosine (ADO) from released adenine nucleotides. ADO, via A2A receptors (A2ARs), is a potent modulator of neuromuscular and immunological responses. The pivotal role of ecto-5'-nucleotidase/CD73, in controlling extracellular ADO formation, prompted us to investigate its role in a rat model of experimental autoimmune myasthenia gravis (EAMG). Results show that CD4(+)CD25(+)FoxP3(+) regulatory T cells express lower amounts of ecto-5'-nucleotidase/CD73 as compared to controls. Reduction of endogenous ADO formation might explain why proliferation of CD4(+) T cells failed upon blocking A2A receptors activation with ZM241385 or adenosine deaminase in EAMG animals. Deficits in ADO also contribute to neuromuscular transmission failure in EAMG rats. Rehabilitation of A2AR-mediated immune suppression and facilitation of transmitter release were observed by incubating the cells with the nucleoside precursor, AMP. These findings, together with the characteristic increase in serum adenosine deaminase activity of MG patients, strengthen our hypothesis that the adenosinergic pathway may be dysfunctional in EAMG. Given that endogenous ADO formation is balanced by ecto-5'-nucleotidase/CD73 activity and that A2ARs exert a dual role to restore use-dependent neurocompetence and immune suppression in myasthenics, we hypothesize that stimulation of the two mechanisms may have therapeutic potential in MG.
Asunto(s)
5'-Nucleotidasa/metabolismo , Adenosina Desaminasa/sangre , Adenosina/metabolismo , Miastenia Gravis/enzimología , Miastenia Gravis/metabolismo , 5'-Nucleotidasa/deficiencia , Adenosina Desaminasa/deficiencia , Animales , Femenino , Contracción Muscular/genética , Contracción Muscular/inmunología , Contracción Muscular/fisiología , Miastenia Gravis/inmunología , Ratas , Ratas Wistar , Transmisión Sináptica/genética , Linfocitos T Reguladores/metabolismoRESUMEN
Purinergic signalling is remarkably plastic during gastrointestinal inflammation. Thus, selective drugs targeting the "purinome" may be helpful for inflammatory gastrointestinal diseases. The myenteric neuromuscular transmission of healthy individuals is fine-tuned and controlled by adenosine acting on A(2A) excitatory receptors. Here, we investigated the neuromodulatory role of adenosine in TNBS-inflamed longitudinal muscle-myenteric plexus of the rat ileum. Seven-day postinflammation ileitis lacks adenosine neuromodulation, which may contribute to acceleration of gastrointestinal transit. The loss of adenosine neuromodulation results from deficient accumulation of the nucleoside at the myenteric synapse despite the fact that the increases in ATP release were observed. Disparity between ATP outflow and adenosine deficit in postinflammatory ileitis is ascribed to feed-forward inhibition of ecto-5'-nucleotidase/CD73 by high extracellular ATP and/or ADP. Redistribution of NTPDase2, but not of NTPDase3, from ganglion cell bodies to myenteric nerve terminals leads to preferential ADP accumulation from released ATP, thus contributing to the prolonged inhibition of muscle-bound ecto-5'-nucleotidase/CD73 and to the delay of adenosine formation at the inflamed neuromuscular synapse. On the other hand, depression of endogenous adenosine accumulation may also occur due to enhancement of adenosine deaminase activity. Both membrane-bound and soluble forms of ecto-5'-nucleotidase/CD73 and adenosine deaminase were detected in the inflamed myenteric plexus. These findings provide novel therapeutic targets for inflammatory gut motility disorders.
Asunto(s)
5'-Nucleotidasa/metabolismo , Adenosina Desaminasa/metabolismo , Adenosina/metabolismo , Ileítis/inducido químicamente , Ileítis/metabolismo , Animales , Femenino , Masculino , Ratas , Ácido Trinitrobencenosulfónico/toxicidadRESUMEN
BACKGROUND: Chronic musculoskeletal pain involves connective tissue remodeling triggered by inflammatory mediators, such as bradykinin. Fibroblast cells signaling involve changes in intracellular Ca2+ ([Ca2+]i). ATP has been related to connective tissue mechanotransduction, remodeling and chronic inflammatory pain, via P2 purinoceptors activation. Here, we investigated the involvement of ATP in bradykinin-induced Ca2+ signals in human subcutaneous fibroblasts. RESULTS: Bradykinin, via B2 receptors, caused an abrupt rise in [Ca2+]i to a peak that declined to a plateau, which concentration remained constant until washout. The plateau phase was absent in Ca2+-free medium; [Ca2+]i signal was substantially reduced after depleting intracellular Ca2+ stores with thapsigargin. Extracellular ATP inactivation with apyrase decreased the [Ca2+]i plateau. Human subcutaneous fibroblasts respond to bradykinin by releasing ATP via connexin and pannexin hemichannels, since blockade of connexins, with 2-octanol or carbenoxolone, and pannexin-1, with 10Panx, attenuated bradykinin-induced [Ca2+]i plateau, whereas inhibitors of vesicular exocytosis, such as brefeldin A and bafilomycin A1, were inactive. The kinetics of extracellular ATP catabolism favors ADP accumulation in human fibroblast cultures. Inhibition of ectonucleotidase activity and, thus, ADP formation from released ATP with POM-1 or by Mg2+ removal from media reduced bradykinin-induced [Ca2+]i plateau. Selective blockade of the ADP-sensitive P2Y12 receptor with AR-C66096 attenuated bradykinin [Ca2+]i plateau, whereas the P2Y1 and P2Y13 receptor antagonists, respectively MRS 2179 and MRS 2211, were inactive. Human fibroblasts exhibited immunoreactivity against connexin-43, pannexin-1 and P2Y12 receptor. CONCLUSIONS: Bradykinin induces ATP release from human subcutaneous fibroblasts via connexin and pannexin-1-containing hemichannels leading to [Ca2+]i mobilization through the cooperation of B2 and P2Y12 receptors.
Asunto(s)
Adenosina Trifosfato/metabolismo , Bradiquinina/metabolismo , Señalización del Calcio/fisiología , Fibroblastos/metabolismo , Receptor de Bradiquinina B2/metabolismo , Receptores Purinérgicos P2Y12/metabolismo , Adenosina Difosfato/metabolismo , Células Cultivadas , Conexina 43/metabolismo , Conexinas/metabolismo , Humanos , Persona de Mediana Edad , Proteínas del Tejido Nervioso/metabolismoRESUMEN
Changes in the regulation of connective tissue ATP-mediated mechano-transduction and remodeling may be an important link to the pathogenesis of chronic pain. It has been demonstrated that mast cell-derived histamine plays an important role in painful fibrotic diseases. Here we analyzed the involvement of ATP in the response of human subcutaneous fibroblasts to histamine. Acute histamine application caused a rise in intracellular Ca(2+) ([Ca(2+)]i) and ATP release from human subcutaneous fibroblasts via H1 receptor activation. Histamine-induced [Ca(2+)]i rise was partially attenuated by apyrase, an enzyme that inactivates extracellular ATP, and by blocking P2 purinoceptors with pyridoxal phosphate-6-azo(benzene-2,4-disulfonic acid) tetrasodium salt and reactive blue 2. [Ca(2+)]i accumulation caused by histamine was also reduced upon blocking pannexin-1 hemichannels with (10)Panx, probenecid, or carbenoxolone but not when connexin hemichannels were inhibited with mefloquine or 2-octanol. Brefeldin A, an inhibitor of vesicular exocytosis, also did not block histamine-induced [Ca(2+)]i mobilization. Prolonged exposure of human subcutaneous fibroblast cultures to histamine favored cell growth and type I collagen synthesis via the activation of H1 receptor. This effect was mimicked by ATP and its metabolite, ADP, whereas the selective P2Y1 receptor antagonist, MRS2179, partially attenuated histamine-induced cell growth and type I collagen production. Expression of pannexin-1 and ADP-sensitive P2Y1 receptor on human subcutaneous fibroblasts was confirmed by immunofluorescence confocal microscopy and Western blot analysis. In conclusion, histamine induces ATP release from human subcutaneous fibroblasts, via pannexin-1 hemichannels, leading to [Ca(2+)]i mobilization and cell growth through the cooperation of H1 and P2 (probably P2Y1) receptors.
Asunto(s)
Adenosina Trifosfato/metabolismo , Calcio/metabolismo , Proliferación Celular/efectos de los fármacos , Conexinas/metabolismo , Fibroblastos/metabolismo , Agonistas de los Receptores Histamínicos/farmacología , Histamina/farmacología , Proteínas del Tejido Nervioso/metabolismo , Adenosina Difosfato/análogos & derivados , Adenosina Difosfato/metabolismo , Adenosina Difosfato/farmacología , Antibacterianos/farmacología , Antimaláricos/farmacología , Brefeldino A/farmacología , Células Cultivadas , Colágeno Tipo I/biosíntesis , Conexinas/antagonistas & inhibidores , Exocitosis/efectos de los fármacos , Exocitosis/fisiología , Femenino , Fibroblastos/citología , Regulación de la Expresión Génica/efectos de los fármacos , Regulación de la Expresión Génica/fisiología , Histamina/metabolismo , Agonistas de los Receptores Histamínicos/metabolismo , Humanos , Masculino , Mastocitos/citología , Mastocitos/metabolismo , Mefloquina/farmacología , Persona de Mediana Edad , Proteínas del Tejido Nervioso/antagonistas & inhibidores , Octanoles/farmacología , Antagonistas del Receptor Purinérgico P2Y/farmacología , Receptores Histamínicos H1/metabolismo , Receptores Purinérgicos P2Y1/metabolismoRESUMEN
Este estudo transversal foi delineado para avaliar as condições de saúde bucal de trabalhadores da construção civil em município da região centro-oeste do Estado de São Paulo. Foram examinados 219 indivíduos do sexo masculino, com idades entre 17 e 72 anos. O levantamento das condições bucais foi realizado em processo de amostragem aleatória simples, a partir do total de 450 inscritos na MEGA-SIPAT 2000 (Semana Interna de Prevenção de Acidentes do Trabalho). Foi utilizado o índice CPOD (cárie dentária) e necessidade de tratamento odontológico, segundo metodologia proposta pela Organização Mundial da Saúde (1997). Neste estudo, são descritas a prevalência de cárie segundo a idade, ocupação e escolaridade. Entre os 219 trabalhadores examinados, o valor CPOD apurado foi 16,9. Os trabalhadores mais jovens (<25 anos de idade) apresentaram média de 21,3 dentes sem necessidade de tratamento, enquanto os mais velhos mostraram necessidades progressivas de tratamento restaurador e reabilitador (p<0,001). Verificou-se índice CPOD de 15,6 para os trabalhadores de áreas administrativas e 21,7 para os mestres-de-obras, sem significância estatística. Houve aumento do índice CPOD segundo a idade, para todos os grupos de trabalhadores (p<0,001). A necessidade de tratamento auto-referida mostrou-se associada a valores CPOD mais baixos para os indivíduos que relataram resposta positiva, quando comparado àqueles que não apresentavam percepção de tais necessidades (p<0,05). Estas diferenças foram significantes, à análise de variância e teste t de Student. Para os trabalhadores da construção civil, neste estudo, não foram observadas lesões orais importantes, presentes em apenas 2,7% dos indivíduos, apesar da exposição diária a alguns fatores de risco para câncer de boca
Asunto(s)
Humanos , Masculino , Adolescente , Adulto , Persona de Mediana Edad , Anciano , Caries Dental , Enfermedades de la Boca/epidemiología , Encuestas de Salud Bucal , Salud Laboral , Diagnóstico BucalRESUMEN
Este estudo transversal foi delineado para avaliar as condições de saúde bucal de trabalhadores da construção civil em município da região centro-oeste do Estado de São Paulo. Foram examinados 219 indivíduos do sexo masculino, com idades entre 17 e 72 anos. O levantamento das condições bucais foi realizado em processo de amostragem aleatória simples, a partir do total de 450 inscritos na MEGA-SIPAT 2000 (Semana Interna de Prevenção de Acidentes do Trabalho). Foi utilizado o índice CPOD (cárie dentária) e necessidade de tratamento odontológico, segundo metodologia proposta pela Organização Mundial da Saúde (1997). Neste estudo, são descritas a prevalência de cárie segundo a idade, ocupação e escolaridade. Entre os 219 trabalhadores examinados, o valor CPOD apurado foi 16,9. Os trabalhadores mais jovens (<25 anos de idade) apresentaram média de 21,3 dentes sem necessidade de tratamento, enquanto os mais velhos mostraram necessidades progressivas de tratamento restaurador e reabilitador (p<0,001). Verificou-se índice CPOD de 15,6 para os trabalhadores de áreas administrativas e 21,7 para os mestres-de-obras, sem significância estatística. Houve aumento do índice CPOD segundo a idade, para todos os grupos de trabalhadores (p<0,001). A necessidade de tratamento auto-referida mostrou-se associada a valores CPOD mais baixos para os indivíduos que relataram resposta positiva, quando comparado àqueles que não apresentavam percepção de tais necessidades (p<0,05). Estas diferenças foram significantes, à análise de variância e teste t de Student. Para os trabalhadores da construção civil, neste estudo, não foram observadas lesões orais importantes, presentes em apenas 2,7% dos indivíduos, apesar da exposição diária a alguns fatores de risco para câncer de boca.
Asunto(s)
Humanos , Masculino , Adolescente , Adulto , Persona de Mediana Edad , Caries Dental , Enfermedades de la Boca/epidemiología , Encuestas de Salud Bucal , Salud Laboral , Diagnóstico BucalRESUMEN
This cross-sectional study aimed at evaluating the oral health conditions of building construction workers from a city in the mid-west region of São Paulo, Brazil. This study involved 219 male subjects, aged 17 to 72. The definition of a random sample utilized the functional number of each worker as a criterion to the raffle, which took into account all 450 subjects registered in the Working Accidents Prevention Program. The examination of oral health conditions by DMFT index and need of treatment were carried out according to WHO criteria (1997). This paper reports the prevalence of caries according to age, occupation, and educational level. Among the 219 workers examined, the mean DMFT was 16.9. Amongst the younger workers (<25 years-old), 21.3 teeth showed no need of treatment, while the older ones showed increasing treatment needs (p<0.001). The DMFT values were 15.6 for the administrative duties and 21.7 for foremen and bricklayers, although the differences were not statistically significant. The DMFT index showed an increase with age for all groups (p<0.001). The self-reported need of treatment was associated with a smaller DMFT for people that reported a positive response when compared with subjects that did not report these needs (p<0.05). These differences were statistically significant, as tested by ANOVA and Student t test. Among the building construction workers, in this study, important oral lesions were not observed, despite the daily exposition to some risk factors for oral cancer.